RARA CRAFT DATABASE for FDA Medical Devices
PMAP150003S105

FDA DEVICE FACTS

SYNERGY XD Everolimus Eluting Platinum Chromium Coronary Stent System, SYNERGY SHIELD Everolimus Eluting Platinum Chromi

Boston Scientific Corporation

Verified FDA Record identity for medical-device development research. This overview uses only fields stated in the FDA Record and is not a Device Description.医療機器開発の調査用に、確認済みの FDA Record の識別情報を示しています。この概要は FDA Record に記載された項目だけによるもので、機器説明ではありません。

DECISION DATEJanuary 27, 2025PRODUCT CODENIQ

Indications for use

Note that the indications for each stent in the SYNERGY family of stents vary regarding vessel and lesion size. The indications approved in this supplement for the SYNERGY XD, SYNERGY MEGATRON, and SYNERGY SHIELD are listed below.

The SYNERGY™ XD Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, ST-elevation MI (STEMI), non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >2.25 mm to <5.00 mm in diameter in lesions <44 mm in length and for high bleeding risk patients with coronary arteries >2.25 mm to <5.00 mm in diameter in lesions <34 mm in length.

The SYNERGY™ MEGATRON Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those at high risk for bleeding, with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, ST elevation MI, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >3.50 mm to <5.00 mm in diameter in lesions <28 mm in length.

The SYNERGY™ SHIELD Everolimus-Eluting Platinum Chromium Coronary Stent System is indicated for improving luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease, stable angina, unstable angina, ST elevation MI, non-ST elevation MI or documented silent ischemia due to atherosclerotic lesions in native coronary arteries >2.25 mm to <5.00 mm in diameter in lesions <44 mm in length and for high bleeding risk patients with coronary arteries >2.25 mm to <5.00 mm in diameter in lesions <34 mm in length.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: September 2, 2026